vs
OPEN TEXT CORP（OTEX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
OPEN TEXT CORP的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Revvity净利率更高（12.7% vs 12.7%，领先0.1%），Revvity同比增速更快（5.9% vs -0.6%），OPEN TEXT CORP自由现金流更多（$279.4M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs -4.3%）
Open Text Corporation是全球知名的跨国软件企业，专注于信息管理类软件的研发与销售，业务覆盖全球众多国家和地区，可为各行业客户提供成熟的信息管理解决方案，助力企业高效管理数据资产，推进数字化转型落地。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
OTEX vs RVTY — 直观对比
营收规模更大
OTEX
是对方的1.7倍
$772.1M
营收增速更快
RVTY
高出6.4%
-0.6%
净利率更高
RVTY
高出0.1%
12.7%
自由现金流更多
OTEX
多$117.7M
$161.8M
两年增速更快
RVTY
近两年复合增速
-4.3%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $168.1M | $98.4M |
| 毛利率 | 74.0% | — |
| 营业利润率 | 22.0% | 14.5% |
| 净利率 | 12.7% | 12.7% |
| 营收同比 | -0.6% | 5.9% |
| 净利润同比 | -26.9% | 3.9% |
| 每股收益（稀释后） | $0.66 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OTEXRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.3B | $664.8M | ||
| Q4 24 | $1.3B | $729.4M | ||
| Q3 24 | $1.3B | $684.0M | ||
| Q2 24 | $1.4B | $691.7M | ||
| Q1 24 | $1.4B | $649.9M |
净利润OTEXRVTY
| Q4 25 | $168.1M | $98.4M | ||
| Q3 25 | $146.6M | $46.7M | ||
| Q2 25 | $28.8M | $53.9M | ||
| Q1 25 | $92.8M | $42.2M | ||
| Q4 24 | $229.9M | $94.6M | ||
| Q3 24 | $84.4M | $94.4M | ||
| Q2 24 | $248.2M | $55.4M | ||
| Q1 24 | $98.3M | $26.0M |
毛利率OTEXRVTY
| Q4 25 | 74.0% | — | ||
| Q3 25 | 72.8% | 53.6% | ||
| Q2 25 | 72.3% | 54.5% | ||
| Q1 25 | 71.6% | 56.5% | ||
| Q4 24 | 73.3% | — | ||
| Q3 24 | 71.7% | 56.3% | ||
| Q2 24 | 72.5% | 55.7% | ||
| Q1 24 | 73.0% | 54.6% |
营业利润率OTEXRVTY
| Q4 25 | 22.0% | 14.5% | ||
| Q3 25 | 21.0% | 11.7% | ||
| Q2 25 | 13.9% | 12.6% | ||
| Q1 25 | 16.7% | 10.9% | ||
| Q4 24 | 22.2% | 16.3% | ||
| Q3 24 | 16.3% | 14.3% | ||
| Q2 24 | 14.2% | 12.4% | ||
| Q1 24 | 15.7% | 6.8% |
净利率OTEXRVTY
| Q4 25 | 12.7% | 12.7% | ||
| Q3 25 | 11.4% | 6.7% | ||
| Q2 25 | 2.2% | 7.5% | ||
| Q1 25 | 7.4% | 6.4% | ||
| Q4 24 | 17.2% | 13.0% | ||
| Q3 24 | 6.6% | 13.8% | ||
| Q2 24 | 18.2% | 8.0% | ||
| Q1 24 | 6.8% | 4.0% |
每股收益（稀释后）OTEXRVTY
| Q4 25 | $0.66 | $0.86 | ||
| Q3 25 | $0.58 | $0.40 | ||
| Q2 25 | $0.11 | $0.46 | ||
| Q1 25 | $0.35 | $0.35 | ||
| Q4 24 | $0.87 | $0.77 | ||
| Q3 24 | $0.32 | $0.77 | ||
| Q2 24 | $0.91 | $0.45 | ||
| Q1 24 | $0.36 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $919.9M |
| 总债务越低越好 | $6.4B | — |
| 股东权益账面价值 | $4.0B | $7.3B |
| 总资产 | $13.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.58× | — |
8季度趋势，按日历期对齐
现金及短期投资OTEXRVTY
| Q4 25 | $1.3B | $919.9M | ||
| Q3 25 | $1.1B | $931.4M | ||
| Q2 25 | $1.2B | $991.8M | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.1B | $1.2B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $1.3B | $2.0B | ||
| Q1 24 | $1.1B | $1.7B |
总债务OTEXRVTY
| Q4 25 | $6.4B | — | ||
| Q3 25 | $6.4B | — | ||
| Q2 25 | $6.4B | — | ||
| Q1 25 | $6.4B | — | ||
| Q4 24 | $6.4B | — | ||
| Q3 24 | $6.4B | — | ||
| Q2 24 | $6.4B | — | ||
| Q1 24 | $8.4B | — |
股东权益OTEXRVTY
| Q4 25 | $4.0B | $7.3B | ||
| Q3 25 | $4.0B | $7.4B | ||
| Q2 25 | $3.9B | $7.6B | ||
| Q1 25 | $4.1B | $7.6B | ||
| Q4 24 | $4.2B | $7.7B | ||
| Q3 24 | $4.1B | $7.9B | ||
| Q2 24 | $4.2B | $7.9B | ||
| Q1 24 | $4.1B | $7.8B |
总资产OTEXRVTY
| Q4 25 | $13.6B | $12.2B | ||
| Q3 25 | $13.5B | $12.1B | ||
| Q2 25 | $13.8B | $12.4B | ||
| Q1 25 | $13.8B | $12.4B | ||
| Q4 24 | $13.7B | $12.4B | ||
| Q3 24 | $13.8B | $12.8B | ||
| Q2 24 | $14.2B | $13.4B | ||
| Q1 24 | $16.4B | $13.4B |
负债/权益比OTEXRVTY
| Q4 25 | 1.58× | — | ||
| Q3 25 | 1.61× | — | ||
| Q2 25 | 1.62× | — | ||
| Q1 25 | 1.55× | — | ||
| Q4 24 | 1.51× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.52× | — | ||
| Q1 24 | 2.02× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $318.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $279.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 21.1% | 21.0% |
| 资本支出强度资本支出/营收 | 3.0% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.90× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $878.5M | $509.4M |
8季度趋势，按日历期对齐
经营现金流OTEXRVTY
| Q4 25 | $318.7M | $182.0M | ||
| Q3 25 | $147.8M | $138.5M | ||
| Q2 25 | $158.2M | $134.3M | ||
| Q1 25 | $402.2M | $128.2M | ||
| Q4 24 | $348.0M | $174.2M | ||
| Q3 24 | $-77.8M | $147.9M | ||
| Q2 24 | $185.2M | $158.6M | ||
| Q1 24 | $384.7M | $147.6M |
自由现金流OTEXRVTY
| Q4 25 | $279.4M | $161.8M | ||
| Q3 25 | $101.2M | $120.0M | ||
| Q2 25 | $124.0M | $115.5M | ||
| Q1 25 | $373.8M | $112.2M | ||
| Q4 24 | $306.7M | $149.8M | ||
| Q3 24 | $-117.1M | $125.6M | ||
| Q2 24 | $145.2M | $136.6M | ||
| Q1 24 | $348.2M | $129.7M |
自由现金流率OTEXRVTY
| Q4 25 | 21.1% | 21.0% | ||
| Q3 25 | 7.9% | 17.2% | ||
| Q2 25 | 9.5% | 16.0% | ||
| Q1 25 | 29.8% | 16.9% | ||
| Q4 24 | 23.0% | 20.5% | ||
| Q3 24 | -9.2% | 18.4% | ||
| Q2 24 | 10.7% | 19.7% | ||
| Q1 24 | 24.1% | 20.0% |
资本支出强度OTEXRVTY
| Q4 25 | 3.0% | 2.6% | ||
| Q3 25 | 3.6% | 2.6% | ||
| Q2 25 | 2.6% | 2.6% | ||
| Q1 25 | 2.3% | 2.4% | ||
| Q4 24 | 3.1% | 3.4% | ||
| Q3 24 | 3.1% | 3.3% | ||
| Q2 24 | 2.9% | 3.2% | ||
| Q1 24 | 2.5% | 2.7% |
现金转化率OTEXRVTY
| Q4 25 | 1.90× | 1.85× | ||
| Q3 25 | 1.01× | 2.97× | ||
| Q2 25 | 5.49× | 2.49× | ||
| Q1 25 | 4.33× | 3.03× | ||
| Q4 24 | 1.51× | 1.84× | ||
| Q3 24 | -0.92× | 1.57× | ||
| Q2 24 | 0.75× | 2.87× | ||
| Q1 24 | 3.91× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OTEX
| Transferred At Point In Time | $184.2M | 14% |
| Cybersecurity Enterprise Product | $174.5M | 13% |
| Business Network Product | $159.8M | 12% |
| Business Network Cloud Services And Subscriptions | $151.4M | 11% |
| Content Cloud Services And Subscriptions | $137.9M | 10% |
| Cybersecurity SMB Consumer Product | $127.6M | 10% |
| Application Delivery Management Product | $120.1M | 9% |
| IT Operations Management Product | $113.3M | 9% |
| Professional Service And Other | $82.5M | 6% |
| Analytics Product | $58.1M | 4% |
| IT Operations Management Cloud Services And Subscriptions | $7.8M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
